Goldman Sachs analyst Andrea Tan has established a price target of $571 for Madrigal Pharmaceuticals, implying a potential upside of approximately 15.6%. Tan’s projection reflects confidence in Madrigal’s late-stage assets for non-alcoholic steatohepatitis (NASH) and follows a thorough review of clinical trial data, competitive positioning against peers such as Intercept Pharmaceuticals and Gilead Sciences, and anticipated regulatory milestones expected over the next 12 to 18 months.

At the 44th Annual J.P. Morgan Healthcare Conference, CEO Bill Sibold underscored Madrigal’s progress in advancing its lead NASH candidate, highlighting Phase 3 enrollment completion and plans for a pivotal safety update by mid-year. Chief Medical Officer Dr. David Soergel detailed biomarker improvements observed in recent substudies, while CFO Mardi Dier reaffirmed plans to maintain a cash runway extending into late 2027, based on current burn-rate projections.

Over the past twelve months, Madrigal’s shares have swung between multi-hundred-point extremes, reflecting investor sensitivity to clinical readouts and sector rotation trends. The company maintains a market capitalization near $11 billion and averaged daily trading volumes above 400,000 shares in recent sessions. Institutional ownership remains high, with roughly 65% of shares held by mutual funds and hedge funds focused on biotech opportunities.

Madrigal has secured exclusive global rights from Pfizer for ervogastat, a novel agent targeting metabolic associated steatohepatitis (MASH). Under the agreement, Madrigal will combine ervogastat with its proprietary Rezdiffra compound in upcoming Phase 2b studies. The collaboration includes upfront and milestone payments structured to align incentives, and Pfizer remains eligible for tiered royalties on future net sales.